Coated glucose microbeads stimulate enteric hormone release and improve glucose tolerance in Phase 1 and 2 clinical trials
Diabetes, Obesity and Metabolism · 2025
DOI: 10.1111/dom.70135 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Kai Deusch und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology, University of Toronto, Toronto, Canada. Hauptthemen laut MEDLINE: Glucose, Gastrointestinal Hormones, Prediabetic State. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Aphaia Pharma US LLC, Aphaia Pharma AG.
Abstract (Originalsprache)
Aims
Incretin agonists are used to treat obesity and metabolic dysfunction. Instead of systemically delivering high levels of hormone receptor agonists that can lead to adverse effects, we tested and optimized oral microbead formulations that activate endogenous enteroendocrine signalling systems via distal nutrient‐sensing cells. Materials and Methods We report two randomized Phase 1 studies (NCT05713773 and NCT05737927) measuring acute pharmacokinetic/pharmacodynamic responses following consumption of microbeads that deliver glucose to the distal small intestine: these studies compared coating variations and glucose dosing. The primary endpoint was plasma glucagon‐like peptide 1 (GLP‐1) levels; we also measured GLP‐2, PYY, glicentin, oxyntomodulin, glucose‐dependent insulinotropic peptide, C‐peptide, and insulin as exploratory endpoints. In a subsequent randomized Phase 2a trial (NCT05803772), prediabetic subjects consumed a lead formulation or placebo once daily for 6 weeks each in a two‐period, two‐sequence crossover design. Oral glucose tolerance was measured at baseline and following treatment in each sequence, with the primary endpoint being the change in the area under the curve.
Results
Our microbead formulation successfully targeted the distal small intestine and elicited a robust plurihormonal enteroendocrine response; our Phase 2a data show that the lead formulation improved glucose tolerance in pre‐diabetic patients, comparable to results using GLP‐1 mimetics. Adverse events were infrequent and modest.
Conclusions
Targeted glucose release activates endogenous enteroendocrine signalling networks, improves a clinically relevant metabolic endpoint, and has minimal adverse effects. The approach to target native enteroendocrine signalling has disruptive potential for the treatment of metabolic disorders, including obesity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Physiology, University of Toronto, Toronto, Canada.
- Aphaia Pharma AG, Zug, Switzerland.
- Aphaia Pharma US LLC, San Juan, Puerto Rico, USA.
- Galephar Pharmaceutical Research Inc., Humacao, Puerto Rico, USA.
- Institute of Nutritional Medicine, University of Luebeck, Lübeck, Germany.
- Fraunhofer Research Institution for Individualized and Cell-Based Medical Engineering, Lübeck (IMTE), Germany.
ORCID-Profile: Steffen-Sebastian Bolz
Förderung
- Aphaia Pharma US LLC
- Aphaia Pharma AG
Zitieren
APA
Deusch, K., Deboek, A., Sina, C., Capo-Velez, C., Alicea, V., Duller, S., Grafe, S., Lidington, D., Hanchard, J., & Bolz, S. S. (2025). Coated glucose microbeads stimulate enteric hormone release and improve glucose tolerance in Phase 1 and 2 clinical trials. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70135
Vancouver
Deusch K, Deboek A, Sina C, Capo-Velez C, Alicea V, Duller S, et al. Coated glucose microbeads stimulate enteric hormone release and improve glucose tolerance in Phase 1 and 2 clinical trials. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.70135
BibTeX
@article{Deusch2025,
author = {Deusch, Kai and Deboek, Arthur and Sina, Christian and Capo-Velez, Coral and Alicea, Vivianette and Duller, Stephan and Grafe, Susanne and Lidington, Darcy and Hanchard, Julia and Bolz, Steffen-Sebastian},
title = {Coated glucose microbeads stimulate enteric hormone release and improve glucose tolerance in Phase 1 and 2 clinical trials},
journal = {Diabetes, Obesity and Metabolism},
year = {2025},
doi = {10.1111/dom.70135}
}
EUVIMED